X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The license will allow Welton to use the Apisolex excipient worldwide to develop and commercialize a novel formulation of WP-038 (SN-38) to treat colorectal and associated gastro-intestinal cancers.
Lead Product(s): Irinotecan Hydrochloride,Apisolex
Therapeutic Area: Oncology Product Name: WP-038
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Welton Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 20, 2023
Details:
This builds on a decades-long partnership between the two organizations to optimize the delivery of several vaginal products, including the Population Council’s proprietary progestin, Nestorone®, and MIV-150, and manufacturing lead formulations for toxicology.
Lead Product(s): Segesterone Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Nestorone
Highest Development Status: UndisclosedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Population Council
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership October 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
